Listed

Advanced Drainage Systems, Inc.: Form 10-Q for the period ended Dec 31, 2024

Filed with the SEC on Feb 6, 2025 and accepted by EDGAR at Feb 6, 2025, 16:02 ET.

Share

Management's discussion and analysis

As filed, 28,232 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Unless the context otherwise indicates or requires, as used in this Quarterly Report on Form 10-Q (“Form 10-Q”), the terms “we,” “our,” “us,” “ADS” and the “Company” refer to Advanced Drainage Systems, Inc. and its directly- and indirectly-owned subsidiaries as a combined entity, except where it is clear that the terms mean only Advanced Drainage Systems, Inc. exclusive of its subsidiaries. We consolidate our joint ventures for purposes of GAAP, except for our South American Joint Venture.

Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, references to “year” pertain to our fiscal year. For example, 2025 refers to fiscal 2025, which is the period from April 1, 2024 to March 31, 2025.

The following discussion and analysis of the financial condition and results of our operations should be read in conjunction with our Condensed Consolidated Financial Statements and related footnotes included elsewhere in this Form 10-Q and with the audited Consolidated Financial Statements included in our Fiscal 2024 Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2024. In addition to historical condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in the forward-looking statements. For more information, see the section entitled “Forward Looking Statements.”

Overview

ADS is the leading manufacturer of innovative water management solutions in the stormwater and onsite septic wastewater industries, providing superior drainage solutions for use in the construction and agriculture marketplaces. Our innovative products, for which we hold many patents, are used across a broad range of end markets and applications, including non-residential, residential, infrastructure and agriculture applications. We have established a leading position in many of these end markets by leveraging our national sales and distribution platform, industry-acclaimed engineering support, overall product breadth and scale plus manufacturing excellence.

Executive Summary

Third Quarter Fiscal 2025 Results

  • Net sales increased 4.3% to $690.5 million
  • Net income decreased 23.0% to $82.3 million
  • Net income per diluted share decreased 22.3% to $1.04
  • Adjusted EBITDA, a non-GAAP measure, decreased 6.2% to $191.5 million

Net sales increased $28.2 million, or 4.3%, to $690.5 million, as compared to $662.4 million in the prior year quarter. Domestic pipe sales decreased $5.7 million, or 1.6%, to $343.4 million. Domestic allied products & other sales increased $5.0 million, or 3.2%, to $161.5 million. Infiltrator sales increased $31.4 million, or 30.3%, to $135.3 million. The overall increase in domestic Net sales was primarily driven by demand in the residential and infrastructure end markets. International sales decreased $2.6 million, or 4.9%, to $50.4 million.

Gross profit decreased $18.3 million, or 7.0%, to $241.6 million as compared to $259.8 million in the prior year. The decrease in gross profit is primarily driven by unfavorable pricing and material cost, as well as the mix impact from the inclusion of Orenco. This unfavorability was partially offset by favorable volume and mix of construction market and Infiltrator sales.

Selling, general and administrative expenses increased $9.5 million, or 10.4% to $100.8 million, as compared to $91.3 million. As a percentage of Net sales, selling, general and administrative expenses increased to 14.6% as compared to 13.8% in the prior year, primarily due to transaction costs and operating expenses for Orenco.

Adjusted EBITDA, a non-GAAP measure, decreased $12.7 million, or 6.2%, to $191.5 million, as compared to $204.2 million in the prior year. As a percentage of Net sales, Adjusted EBITDA was 27.7% as compared to 30.8% in the prior year.

Year-to-date Fiscal 2025 Results

  • Net sales increased 3.1% to $2,288.5 million
  • Net income decreased 10.1% to $375.8 million
  • Net income per diluted share decreased 9.0% to $4.77

- 20 -

  • Adjusted EBITDA, a non-GAAP measure, decreased 2.6% to $712.5 million

Net sales increased $67.9 million, or 3.1%, to $2,288.5 million, as compared to $2,220.6 million in the prior year. Domestic pipe sales decreased $0.3 million to $1,185.3 million. Domestic allied products & other sales increased $23.8 million, or 4.6%, to $544.5 million. Infiltrator sales increased $51.1 million, or 14.9%, to $394.0 million. The overall increase in domestic Net sales was primarily driven by demand in the residential and infrastructure end markets. International sales decreased $6.7 million, or 3.9%, to $164.6 million.

Gross profit decreased $26.0 million, or 2.9%, to $868.0 million as compared to $894.0 million in the prior year. The decrease in gross profit is primarily driven by unfavorable pricing and material cost, partially offset by favorable manufacturing costs and volume.

Selling, general and administrative expenses increased $19.4 million, or 7.2% to $289.0 million, as compared to $269.5 million. As a percentage of Net sales, selling, general and administrative expenses were largely flat at 12.6% as compared to 12.1% in the prior year.

Adjusted EBITDA, a non-GAAP measure, decreased $19.2 million, or 2.6%, to $712.5 million, as compared to $731.8 million in the prior year. As a percentage of Net sales, Adjusted EBITDA was 31.1% as compared to 33.0% in the prior year.

Results of Operations

Comparison of the Three Months Ended December 31, 2024 to the Three Months Ended December 31, 2023

The following table summarizes our operating results as a percentage of Net sales that have been derived from our Condensed Consolidated Financial Statements for the periods presented. We believe this presentation is useful to investors in comparing historical results.

(In thousands)

Consolidated Statements of Operations data: For the Three Months Ended December 31, 2024 2023
Net sales $690,538 100.0% $662,367 100.0%
Cost of goods sold 448,944 65.0 402,518 60.8
Gross profit 241,594 35.0 259,849 39.2
Selling, general and administrative 100,778 14.6 91,289 13.8
(Gain) loss on disposal of assets and costs from exit and disposal activities (477) (0.1) 2,512 0.4
Intangible amortization 14,429 2.1 12,782 1.9
Income from operations 126,864 18.4 153,266 23.1
Interest expense 23,094 3.3 22,331 3.4
Interest income and other, net (4,792) (0.7) (4,772) (0.7)
Income before income taxes 108,562 15.7 135,707 20.5
Income tax expense 27,091 3.9 30,131 4.5
Equity in net income of unconsolidated affiliates (818) (0.1) (1,304) (0.2)
Net income 82,289 11.9 106,880 16.1
Less: net income attributable to noncontrolling interest 1,058 0.2 1,241 0.2
Net income attributable to ADS $81,231 11.8% $105,639 15.9%

Net sales - The following table presents Net sales to external customers by reportable segment for the three months ended December 31, 2024 and 2023.

(Amounts in thousands)

2024 2023 $ Variance % Variance
Pipe $343,403 $349,104 $(5,701) (1.6)%
Infiltrator 135,301 103,871 31,430 30.3
International 50,363 52,948 (2,585) (4.9)
Allied Products & Other 161,471 156,444 5,027 3.2
Total Consolidated $690,538 $662,367 $28,171 4.3%

- 21 -

Our consolidated Net sales for the three months ended December 31, 2024 increased by $28.2 million, or 4.3%, compared to the same period in fiscal 2024. The overall increase in domestic Net sales was primarily driven by demand in the residential and infrastructure end markets. Net sales of $25.4 million of Orenco drove the increase in Net sales for Infiltrator, while the volume growth in Domestic Pipe was offset by unfavorable price/mix impact. For the international segment, the decrease was driven by decreased volume as well as unfavorable price/mix.

Cost of goods sold and Gross profit - The following table presents gross profit by reportable segment for the three months ended December 31, 2024 and 2023.

(Amounts in thousands)

2024 2023 $ Variance % Variance
Pipe $69,334 $99,567 $(30,233) (30.4)%
Infiltrator 69,444 62,780 6,664 10.6
International 10,466 12,817 (2,351) (18.3)
Allied Products & Other 90,601 86,606 3,995 4.6
Intersegment eliminations 1,749 (1,921) 3,670 (191.0)
Total gross profit $241,594 $259,849 $(18,255) (7.0)%

Our consolidated Cost of goods sold for the three months ended December 31, 2024 increased by $46.4 million, or 11.5%, and our consolidated Gross profit decreased by $18.3 million, or 7.0%, compared to the same period in fiscal 2024. The decrease in gross profit for Domestic Pipe is primarily driven by unfavorable pricing and material cost, partially offset by volume. The increase in gross profit for Infiltrator was primarily driven by Orenco.

Selling, general and administrative expenses

(Amounts in thousands)

Three Months Ended December 31, 2024 2023
Selling, general and administrative expenses $100,778 $91,289
% of Net sales 14.6% 13.8%

Selling, general and administrative expenses for the three months ended December 31, 2024 increased $9.5 million from the same period in fiscal 2024 and as a percentage of Net sales, increased by 0.8%. The increase in selling, general and administrative expenses was primarily due to transaction costs of $5.9 million and operating expenses for Orenco.

Interest expense - Interest expense increased $0.8 million in the three months ended December 31, 2024 compared to the same period in the previous fiscal year. The increase was primarily due to an increase in interest rates.

Income tax expense - The following table presents the effective tax rates for the periods presented:

Three Months Ended December 31, 2024 2023
Effective tax rate 25.0% 22.2%

The change in the effective tax rate for the three months ended December 31, 2024 was primarily related to the discrete income tax benefits for the amended state tax returns and the federal return to provision adjustment in the prior period. See “Note 10. Income Taxes” for additional information.

- 22 -

Comparison of the Nine Months Ended December 31, 2024 to the Nine Months Ended December 31, 2023

The following table summarizes our operating results as a percentage of Net sales that have been derived from our Condensed Consolidated Financial Statements for the periods presented. We believe this presentation is useful to investors in comparing historical results.

(In thousands)

Consolidated Statements of Operations data: For the Nine Months Ended December 31, 2024 2023
Net sales $2,288,484 100.0% $2,220,633 100.0%
Cost of goods sold 1,420,495 62.1 1,326,647 59.7
Gross profit 867,989 37.9 893,986 40.3
Selling, general and administrative 288,962 12.6 269,525 12.1
Loss (gain) on disposal of assets and costs from exit and disposal activities 432 — (10,669) (0.5)
Intangible amortization 38,140 1.7 38,376 1.7
Income from operations 540,455 23.6 596,754 26.9
Interest expense 69,074 3.0 65,984 3.0
Interest income and other, net (18,864) (0.8) (15,827) (0.7)
Income before income taxes 490,245 21.4 546,597 24.6
Income tax expense 117,897 5.2 132,665 6.0
Equity in net income of unconsolidated affiliates (3,437) (0.2) (3,880) (0.2)
Net income 375,785 16.4 417,812 18.8
Less: net income attributable to noncontrolling interest 2,770 0.1 2,719 0.1
Net income attributable to ADS $373,015 16.3% $415,093 18.7%

Net sales - The following table presents Net sales to external customers by reportable segment for the nine months ended December 31, 2024 and 2023.

(Amounts in thousands)

2024 2023 $ Variance % Variance
Pipe $1,185,316 $1,185,630 $(314) —%
Infiltrator 394,011 342,956 51,055 14.9
International 164,621 171,330 (6,709) (3.9)
Allied Products & Other 544,536 520,717 23,819 4.6
Total Consolidated $2,288,484 $2,220,633 $67,851 3.1%

Our consolidated Net sales for the nine months ended December 31, 2024 increased by $67.9 million, or 3.1%, compared to the same period in fiscal 2024. The overall increase in domestic Net sales was primarily driven by demand in the residential and infrastructure end markets. Net sales for Infiltrator were also driven by improved price/mix and the acquisition of Orenco, while the volume growth in Domestic Pipe was offset by unfavorable price/mix impact. For the international segment, the decrease was driven by unfavorable price/mix.

Cost of goods sold and Gross profit - The following table presents gross profit by reportable segment for the nine months ended December 31, 2024 and 2023.

(Amounts in thousands)

2024 2023 $ Variance % Variance
Pipe $285,479 $355,016 $(69,537) (19.6)%
Infiltrator 229,408 199,685 29,723 14.9
International 44,634 47,711 (3,077) (6.4)
Allied Products & Other 308,288 296,004 12,284 4.1
Intersegment eliminations 180 (4,430) 4,610 (104.1)
Total gross profit $867,989 $893,986 $(25,997) (2.9)%

- 23 -

Our consolidated Cost of goods sold for the nine months ended December 31, 2024 increased by $93.8 million, or 7.1%, and our consolidated Gross profit decreased by $26.0 million, or 2.9%, compared to the same period in fiscal 2024. The decrease in gross profit for Domestic Pipe is primarily driven by unfavorable pricing and material cost, partially offset by favorable manufacturing costs. The increase in gross profit for Infiltrator was driven by favorable pricing, improved material cost and the acquisition of Orenco.

Selling, general and administrative expenses

(Amounts in thousands)

Nine Months Ended December 31, 2024 2023
Selling, general and administrative expenses $288,962 $269,525
% of Net sales 12.6% 12.1%

Selling, general and administrative expenses for nine months ended December 31, 2024 increased $19.4 million from the same period in fiscal 2024 and as a percentage of Net sales, increased by 0.5%. This increase is primarily due to higher commissions from the increase in volume, as well as continued investments in talent to support strategic areas such as engineering and product development. The increase in selling, general and administrative expenses was also due to transaction costs of $8.6 million and operating expenses for Orenco.

Loss (gain) on disposal of assets and costs from exit and disposal activities - The gain on disposal in fiscal 2024 was due to the sale of Spartan Concrete, Inc.

Interest expense - Interest expense increased $3.1 million in the nine months ended December 31, 2024 compared to the same period in the previous fiscal year. The increase was primarily due to increased interest rates.

Interest income and other, net - Interest income and other, net increased by $3.0 million for the nine months ended December 31, 2024 compared to the same period in the previous fiscal year primarily due to increased cash.

Income tax expense - The following table presents the effective tax rates for the nine months ended December 31, 2024 and 2023.

Nine Months Ended December 31, 2024 2023
Effective tax rate 24.0% 24.3%

See “Note 10. Income Taxes” for additional information.

Adjusted EBITDA and Adjusted EBITDA Margin - Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures, have been presented in this Form 10-Q as supplemental measures of financial performance that are not required by, or presented in accordance with GAAP and should not be considered as alternatives to net income as measures of financial performance or cash flows from operations or any other performance measure derived in accordance with GAAP. We calculate Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, stock-based compensation expense, non-cash charges and certain other expenses. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by Net sales.

Adjusted EBITDA and Adjusted EBITDA Margin are included in this Form 10-Q because they are key metrics used by management and our board of directors to assess our consolidated financial performance. These non-GAAP financial measures are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. In addition to covenant compliance and executive performance evaluations, we use these non-GAAP financial measures to supplement GAAP measures of performance to evaluate the effectiveness of our consolidated business strategies, to make budgeting decisions and to compare our performance against that of other peer companies using similar measures. We use Adjusted EBITDA Margin to evaluate our ability to generate profitable sales.

Adjusted EBITDA and Adjusted EBITDA Margin contain certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs, cash expenditures to replace assets being depreciated and amortized and interest expense, or the cash requirements necessary to service interest on principal payments on our indebtedness. In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future we will incur expenses that are the same as or similar to some of the adjustments in this presentation, such as stock-based compensation expense, derivative fair value adjustments, and foreign currency transaction losses. Management compensates for these limitations by relying on our GAAP results and using non-GAAP measures on a supplemental basis.

- 24 -

The following table presents a reconciliation of Adjusted EBITDA to Net income, the most comparable GAAP measure, for each of the periods presented.

(In thousands)

Three Months Ended December 31, 2024 2023 Nine Months Ended December 31, 2024 2023
Net income $82,289 $106,880 $375,785 $417,812
Depreciation and amortization 47,766 38,053 133,671 112,014
Interest expense 23,094 22,331 69,074 65,984
Income tax expense 27,091 30,131 117,897 132,665
EBITDA 180,240 197,395 696,427 728,475
(Gain) loss on disposal of assets and costs from exit and disposal activities (477) 2,512 432 (10,669)
Stock-based compensation expense 7,798 7,402 21,758 23,636
Transaction costs(a) 5,924 1,030 8,619 3,054
Interest income (4,545) (6,515) (18,478) (15,141)
Other adjustments(b) 2,545 2,382 3,775 2,414
Adjusted EBITDA $191,485 $204,206 $712,533 $731,769
Adjusted EBITDA Margin 27.7% 30.8% 31.1% 33.0%

(a) Represents expenses recorded related to legal, accounting and other professional fees incurred in connection with business or asset acquisitions and dispositions.

(b) Includes derivative fair value adjustments, foreign currency transaction (gains) losses, legal settlements, inventory step-up costs, the proportionate share of interest, income taxes, depreciation and amortization related to the South American Joint Venture, which is accounted for under the equity method of accounting and executive retirement expense.

Liquidity and Capital Resources

Historically, we have funded our operations through internally generated cash flow supplemented by debt financings, equity issuance and finance and operating leases. These sources have been sufficient historically to fund our primary liquidity requirements, including working capital, capital expenditures, debt service and dividend payments for our common stock. From time to time, we may explore additional financing methods and other means to raise capital. There can be no assurance that any additional financing will be available to us on acceptable terms or at all.

Free Cash Flow - Free cash flow is a non-GAAP financial measure that comprises cash flow from operations less capital expenditures and is used by management and our Board of Directors to assess our ability to generate cash. Accordingly, free cash flow has been presented as a supplemental measure of liquidity that is not required by, or presented in accordance with GAAP, because management believes that free cash flow provides useful information to investors and others in understanding and evaluating our ability to generate cash flow from operations after capital expenditures. Free cash flow is not a GAAP measure of our liquidity and should not be considered as an alternative to cash flow from operating activities as a measure of liquidity or any other liquidity measure derived in accordance with GAAP. Our measure of free cash flow is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

The following table presents a reconciliation of free cash flow to cash provided by operating activities, the most comparable GAAP measure, for each of the periods presented:

(Amounts in thousands)

Nine Months Ended December 31, 2024 2023
Net cash provided by operating activities $540,264 $700,262
Capital expenditures (166,410) (136,385)
Free Cash Flow $373,854 $563,877

- 25 -

The following table presents key liquidity metrics utilized by management including the leverage ratio which is calculated as net debt divided by the trailing twelve months Adjusted EBITDA:

(Amounts in thousands)

December 31, 2024
Total debt (debt and finance lease obligations) $1,409,621
Cash 488,859
Net debt (total debt less cash) 920,762
Leverage Ratio 1.0

The following table summarizes our available liquidity for the period presented:

(Amounts in thousands)

December 31, 2024
Revolver capacity $600,000
Less: outstanding borrowings —
Less: letters of credit (10,450)
Revolver available liquidity $589,550

In addition to the available liquidity above, we have the ability to borrow up to $1.3 billion under our Senior Secured Credit Facility, subject to leverage ratio restrictions.

As of December 31, 2024, we had $29.8 million in cash that was held by our foreign subsidiaries, including $19.5 million held by our Canadian subsidiaries. We continue to evaluate our strategy regarding foreign cash, but our earnings in foreign subsidiaries still remain indefinitely reinvested, except for Canada. We plan to repatriate earnings from Canada and believe that there will be no additional tax costs associated with the repatriation of such earnings other than any potential non-U.S. withholding taxes.

Working Capital and Cash Flows

As of December 31, 2024, we had $1,078.4 million in liquidity, including $488.9 million of cash and $589.6 million in borrowings available under our Revolving Credit Agreement, net of outstanding letters of credit. We believe that our cash on hand, together with the availability of borrowings under our Credit Agreement and other financing arrangements and cash generated from operations, will be sufficient to meet our working capital requirements, anticipated capital expenditures, and scheduled principal and interest payments on our indebtedness for at least the next twelve months.

Working Capital - Working capital decreased to $857.0 million as of December 31, 2024, from $860.3 million as of March 31, 2024. The decrease in working capital is primarily due to the seasonality of accounts receivable and inventory offset by changes in accounts payable due to the timing of payments.

(Amounts in thousands)

Nine Months Ended December 31, 2024 2023
Net cash provided by operating activities $540,264 $700,262
Net cash used in investing activities (402,889) (115,879)
Net cash used in financing activities (135,944) (236,436)

Operating Cash Flows - Cash flows from operating activities decreased $160.0 million during the nine months ended December 31, 2024 primarily driven by a reduction in net income and changes in working capital.

Investing Cash Flows - Cash flows used in investing activities during the nine months ended December 31, 2024 increased by $287.0 million compared to the same period in fiscal 2024. The increase in cash used in investing activities was due to the acquisition of Orenco in fiscal 2025 and increased capital expenditures partially offset by the sale of Spartan Concrete in fiscal 2024.

Capital expenditures totaled $166.4 million and $136.4 million for the nine months ended December 31, 2024 and 2023, respectively. Our capital expenditures for the nine months ended December 31, 2024 were used primarily to support facility expansions, equipment replacements and technology improvement initiatives. We also acquired $84.3 million of property, plant and equipment under finance leases, which includes transportation equipment to update our fleet of trucks and trailers.

- 26 -

We currently anticipate that we will make capital expenditures of approximately $225 million in fiscal year 2025, including approximately $100 million of open orders as of December 31, 2024. Such capital expenditures are expected to be financed using funds generated by operations.

Financing Cash Flows - During the nine months ended December 31, 2024, cash used in financing activities included the repurchase of common stock of $69.9 million, $37.3 million of dividend payments, $17.8 million of payments of finance lease obligations and $10.6 million for shares withheld for tax purposes.

During the nine months ended December 31, 2023, cash used in financing activities included the repurchase of common stock of $178.2 million, $33.1 million of dividend payments, and $8.9 million for shares withheld for tax purposes.

Financing Transactions - There have been no changes in our debt disclosures from those disclosed in “Liquidity and Capital Resources” in our Fiscal 2024 Form 10-K. We are in compliance with our debt covenants as of December 31, 2024.

Off-Balance Sheet Arrangements

Excluding the guarantees of 50% of certain debt of our unconsolidated South American Joint Venture as further discussed in “Note 7. Related Party Transactions” to the Condensed Consolidated Financial Statements, we do not have any other off-balance sheet arrangements. As of December 31, 2024, our South American Joint Venture had no outstanding debt subject to our guarantees. We do not believe that this guarantee will have a current or future effect on our financial condition, results of operations, liquidity or capital resources.

Critical Accounting Policies and Estimates

There have been no changes in critical accounting policies from those disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Fiscal 2024 Form 10-K, except as disclosed in “Note 1. Background and Summary of Significant Accounting Policies.”

Market risk

As filed, 1,288 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are subject to various market risks, primarily related to changes in interest rates, credit, raw material supply prices and, to a lesser extent, foreign currency exchange rates. Our financial position, results of operations or cash flows may be negatively impacted in the event of adverse movements in the respective market rates or prices in each of these risk categories. Our exposure in each category is limited to those risks that arise in the normal course of business, as we do not engage in speculative, non-operating transactions. Our exposure to market risk has not materially changed from what we previously disclosed in Part II. Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” of our Fiscal 2024 Form 10-K except as disclosed below.

Interest Rate Risk - We are subject to interest rate risk associated with our bank debt. A 1.0% increase in interest rates on our variable-rate debt would increase our annual forecasted interest expense by approximately $4.1 million based on our borrowings as of December 31, 2024. Assuming the Revolving Credit Facility is fully drawn, each 1.0% increase or decrease in the applicable interest rate would change our interest expense by approximately $10.1 million, for the twelve months ended December 31, 2024.

Controls and procedures

As filed, 1,731 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures - The Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) are responsible for evaluating the effectiveness of our disclosure controls and procedures as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”), rules 13a-15(e) and 15d-15(e). The Company’s disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in the Company’s reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the Company’s CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, our CEO and CFO concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting - There were no changes in the Company’s internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the three months

- 27 - ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, internal control over financial reporting.

Risk factors

As filed, 553 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Important risk factors that could affect our operations and financial performance, or that could cause results or events to differ from current expectations, are described in “Part I, Item 1A — Risk Factors” of our Fiscal 2024 Form 10-K. These factors are further supplemented by those discussed in “Part II, Item 7A — Quantitative and Qualitative Disclosures about Market Risk” of our Fiscal 2024 Form 10-K and in “Part I, Item 3 — Quantitative and Qualitative Disclosures about Market Risk” and “Part II, Item 1 — Legal Proceedings” of this Form 10-Q.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-10-01 to 2024-12-31$690.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2024-04-01 to 2024-12-31$2.29bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Gross profit3 months2024-10-01 to 2024-12-31$241.6mus-gaap:GrossProfit
Gross profit9 months2024-04-01 to 2024-12-31$868.0mus-gaap:GrossProfit
Operating income3 months2024-10-01 to 2024-12-31$126.9mus-gaap:OperatingIncomeLoss
Operating income9 months2024-04-01 to 2024-12-31$540.5mus-gaap:OperatingIncomeLoss
Income tax3 months2024-10-01 to 2024-12-31$27.1mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2024-04-01 to 2024-12-31$117.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-10-01 to 2024-12-31$81.2mus-gaap:NetIncomeLoss
Net income9 months2024-04-01 to 2024-12-31$373.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-10-01 to 2024-12-31$1.04us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2024-04-01 to 2024-12-31$4.77us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-10-01 to 2024-12-31$1.05us-gaap:EarningsPerShareBasic
Basic EPS9 months2024-04-01 to 2024-12-31$4.81us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-10-01 to 2024-12-3178,115,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2024-04-01 to 2024-12-3178,196,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2024-04-01 to 2024-12-31$540.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2024-04-01 to 2024-12-31$166.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2024-04-01 to 2024-12-31$37.3mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2024-04-01 to 2024-12-31$69.9mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2024-12-31$488.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-12-31$1.25bnus-gaap:AssetsCurrent
Total assetsAt period end2024-12-31$3.60bnus-gaap:Assets
Current liabilitiesAt period end2024-12-31$388.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-12-31$2.04bnus-gaap:Liabilities
Long-term debtAt period end2024-12-31$1.25bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2024-12-31$10.6mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2024-12-31$1.45bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001604028-25-000005. Last ingested by Listed: Nov 5, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.